Athenex dis­clos­es pa­tient death, clin­i­cal hold on CAR-NKT tri­al as it seeks strate­gic al­ter­na­tives

A neu­rob­las­toma pa­tient has died af­ter re­ceiv­ing Athenex’s nat­ur­al killer cell ther­a­py, trig­ger­ing a clin­i­cal hold, the com­pa­ny re­vealed.

Bay­lor Col­lege of Med­i­cine, which is run­ning the tri­al, has iden­ti­fied some of the con­di­tions lead­ing up to the pa­tient’s death and is “de­vis­ing a safe­ty risk mit­i­ga­tion plan” to re­open the tri­al, ac­cord­ing to Athenex. It did not re­turn re­quests for com­ment on when the pa­tient’s death oc­curred.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER